Breaking News Instant updates and real-time market news.

ENDP

Endo

$19.81

0.18 (0.92%)

10:38
10/14/16
10/14
10:38
10/14/16
10:38

Endo rises 4% to $20.61 in early trading

Analysts at Guggenheim said their sum-of-the-parts analysis indicate the stock is worth $30-$51 per share in a note to investors earlier, according to Bloomberg.

ENDP Endo
$19.81

0.18 (0.92%)

09/23/16
JANY
09/23/16
UPGRADE
Target $4
JANY
Buy
BioDelivery Sciences upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich upgraded BioDelivery Sciences (BDSI) to Buy from Neutral, stating that Endo International (ENDP) has "not yet announced, but clearly won" preferred status for Belbuca relative to market leader Butrans on United Healthcare's Prescription Drug List. Endo's Belbuca utilizes BioDelivery Sciences' patented BioErodible MucoAdhesive drug delivery technology. The United contract, paired with the fact that BioDelivery has announced five contract wins for Bunavail since July, put Bunavail on a path to show meaningful growth in 2017, said Trbovich, who maintains his $4 fair value estimate on the stock.
09/26/16
OPCO
09/26/16
NO CHANGE
OPCO
Perform
CEO change signals new direction for Endo, says Oppenheimer
Oppenheimer analyst Marcus Ho was not entirely surprised by the appointment of Paul Campanelli to President and CEO of Endo, noting that the company has been hit hard by the recent negative commentary surrounding opioids and the erosion in the generics pricing environment. The analyst points out that management reaffirmed Q3 and full-year 2016 guidance and is now directionally focused more on operational execution, with an emphasis on pipeline and paragraph IV opportunities on the generics side and product development on the branded side. He reiterates a Perform rating on the shares.
09/29/16
NORL
09/29/16
UPGRADE
NORL
Outperform
Endo upgraded to Outperform from Market Perform at Northland
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.